Skip to content

High Intensity Exercise in Children With MCADD

Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCADD) and Exercise

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06796530
Acronym
MCADD-EX
Enrollment
8
Registered
2025-01-28
Start date
2025-01-20
Completion date
2026-03-19
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medium Chain Acyl CoA Dehydrogenase Deficiency

Keywords

MCADD, CPET, high intensity exercise, acylcarnitine

Brief summary

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare genetic disorder affecting the body's ability to break down certain fats (β-oxidation) for energy, leading to symptoms like hypoketotic hypoglycaemia, jaundice, cardiomyopathy and seizures. responsible for the dehydrogenation step of fatty acids with chain lengths between 6 and 12 carbons as they undergo beta-oxidation in the mitochondria. Deficiency in MCAD can result in energy deficiency, the accumulation of acylcarnitine's and low serum carnitine concentrations. The primary objective of the pilot study is to analyse the effects of high-intensity exercise (cardiopulmonary exercise testing (CPET) & high intensity circuit exercises ) on metabolic parameters and safety. This research is a pilot study comparing four patients with MCADD to four control subjects with the same characteristics. Blood samples are collected for analysis of substrate utilization.

Detailed description

The primary objective of the study is to analyse the effects of high-intensity exercise (CPET & high intensity circuit exercises) on metabolic parameters and safety. Since exercise is tested approximately two hours after a meal, we expect few symptoms, as fat metabolism is only minimally engaged at this intensity. Of interest could be the recovery from exercise, as fat metabolism is presumably activated during this phase. Each MCADD-patient will attend two experimental visits. On the day of the first visit, the patient will arrive at UZ Gent after 1.5-hours following the meal. After 30 minutes, they will perform a cardiopulmonary exercise test (CPET) on a cycle ergometer. The standard CPET protocol that will be used is as follows: first, three minutes of cycling at a constant load (body weight (kg) / 2) in Watts), followed by a maximal exercise test (Ramp protocol: (body weight (kg) / 4) in Watts per minute). During the cycling test, gas exchange (spirometry) is measured, and an ECG is taken. If no symptoms are observed, the patient may return home. On the second test day, two hours before the test, a breakfast will be consumed. 1.5-hours following the meal, the patient will arrive at UZ Gent, where a heart monitor will be placed, and an intravenous line will be inserted. Following this, the patient will undergo a high-intensity exercise circuit. Blood samples will be taken before and after the exercise at various intervals: immediately, after 30 minutes, 1 hour, and 1.5-hours. Also, RER will be determined at each timepoint using indirect calorimetry. If no symptoms appear, the patient may return home. The patient will report symptoms for the 48 hours following the test. In the blood samples, measures of substrate utilization will be monitored: Glucose, lactate, acylcarnitine levels, free fatty acids (FFA). Also a marker of muscle damage will be assessed (creatine kinase). Additional measures include: anthropometric measurements, including weight and height, physical activity through the children physical activity questionnaire).

Interventions

Participants undergo a CPET on a stationary bike, measuring gas exchange, ECG, and other parameters. The protocol includes 3 minutes of cycling at a constant load (body weight/2 in Watts), followed by a maximal effort test with an incremental load (Ramp protocol body weight (kg) / 4 in Watts per minute).

PROCEDUREHigh-intensity circuit training

The patients will undergo a 10-minute warm-up, followed by \~30 high intensity exercise circuit.

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

One group of MCADD patients and one healthy control group. Both groups undergo the same exercise protocols and metabolic assessments to compare physiological responses and recovery. The MCADD group's responses are compared to those of the control group to analyze differences in metabolic parameters and safety outcomes following high-intensity exercise.

Eligibility

Sex/Gender
ALL
Age
8 Years to 17 Years
Healthy volunteers
Yes

Inclusion criteria

* 8-17y old * Control subjects matched by sex, age, and self reported Tanner stage. * All children: height and weight between P5-P95

Exclusion criteria

* No daily medication use * No conditions other than MCADD that restrict sports participation or physiology (e.g., no heart diseases, diabetes). * \< P5 or \> P95 on the height-weight curve * No neuromotor developmental delay (e.g., delayed achievement of motor milestones) * No recent immobilization (\<6 months) * No surgeries involving the musculoskeletal system

Design outcomes

Primary

MeasureTime frameDescription
glucoseFrom start of exercise until 1.5 hours post-exercise.Analysis of glucose in blood samples taken before, immediately after, and at intervals (30 minutes, 1 hour, and 1.5 hours) following high-intensity exercise.

Secondary

MeasureTime frameDescription
Cardiorespiratory response during CPETDuring CPET (approximately 30 minutes).Measurement of maximal oxygen uptake during the cardiopulmonary exercise test (CPET) on a stationary bike.
Safety: Incidence of adverse events during and after exercise.During and up to 48 hours post-exercise.Monitoring and recording of any symptoms, adverse events, or complications during exercise and the following 48 hours
acylcarnitinesFrom the end of the exercise circuit until 1.5 hours post-exercise.Monitoring of acylcarnitines before and after high intensity exercise

Countries

Belgium

Contacts

PRINCIPAL_INVESTIGATORPatrick Verloo, MD

University Hospital, Ghent

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026